Inactive Instrument

Analyst Reco. Avalanche Biotechnologies Inc Nasdaq

Equities

US05337G1076

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target	30/04	MT
Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating	29/04	MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	19/03	MT
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2	02/11	MT
Chardan Upgrades Adverum Biotechnologies to Buy From Neutral, Expecting Positive Outcome From Ongoing LUNA Trial, Raises Price Target to $4 From $2	11/23/11	MT
Ladenburg Thalmann Starts Adverum Biotechnologies at Buy With $2 Price Target	07/23/07	MT
RBC Cuts Price Target on Adverum Biotechnologies to $3 From $5, Maintains Sector Perform, Speculative Risk	11/22/11	MT
Chardan Trims Price Target on Adverum Biotechnologies to $2 From $2.50, Retains Neutral Rating	11/22/11	MT
Chardan Research Trims Adverum Biotechnologies' Price Target to $2.50 From $3, Maintains Neutral Rating	12/22/12	MT
Truist Securities Upgrades Adverum Biotechnologies to Buy From Hold, Adjusts Price Target to $4 From $3	07/22/07	MT
CORRECTION : --Goldman Sachs Downgrades Advantage Solutions to Neutral From Buy; Price Target is $7	04/22/04	MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $3 From $10	23/21/23	MT
ADVERUM BIOTECHNOLOGIES : Chardan Adjusts Price Target on Adverum Biotechnologies to $3 From $5 After Eye Drug Cancellation, Maintains Neutral Rating	23/21/23	MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Adjusts Adverum Biotechnologies' Price Target to $2 from $5, Keeps Market Perform Rating	23/21/23	MT
ADVERUM BIOTECHNOLOGIES : Cantor Fitzgerald Downgrades Adverum Biotechnologies to Neutral From Overweight, Adjusts Price Target to $3 From $23	23/21/23	MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Downgrades Adverum Biotechnologies to Market Perform From Outperform; Price Target is $5	03/21/03	MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target for Adverum Biotechnologies to $10 From $28, Maintains Buy Rating	29/21/29	MT
ADVERUM BIOTECHNOLOGIES : Truist Securities Downgrades Adverum Biotechnologies to Hold From Buy, Adjusts PT to $9 From $30	29/21/29	MT
ADVERUM BIOTECHNOLOGIES : Chardan Downgrades Adverum Biotechnologies to Neutral Rating From Buy on Eye Drug Side Effects, Adjusts Price Target to $5 From $20	29/21/29	MT
ADVERUM BIOTECHNOLOGIES : RBC Capital Downgrades Adverum Biotechnologies to Sector Perform Rating From Outperform, Lowers PT to $6 From $30	29/21/29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Avalanche Biotechnologies Inc Nasdaq

Equities

US05337G1076

Analyst Reco.

Filters